AI Engines For more Details: Perplexity Kagi Labs You
Irritable Bowel Syndrome (IBS): Dicyclomine hydrochloride is commonly used to relieve symptoms of irritable bowel syndrome, including abdominal pain, cramping, bloating, and discomfort. It works by relaxing smooth muscles in the GI tract, which can help reduce spasms and alleviate symptoms associated with IBS.
Functional GI Disorders: Dicyclomine hydrochloride may also be used to treat other functional gastrointestinal disorders characterized by smooth muscle spasms, such as functional dyspepsia and functional abdominal pain. It can help reduce visceral hypersensitivity and improve symptoms of pain and discomfort.
Anticholinergic Effects: Dicyclomine hydrochloride is an anticholinergic medication that works by blocking the action of acetylcholine, a neurotransmitter involved in smooth muscle contraction. By inhibiting acetylcholine's effects on the GI tract, dicyclomine hydrochloride helps relax smooth muscles and reduce hypermotility and spasms.
Symptomatic Relief: Dicyclomine hydrochloride provides symptomatic relief of GI symptoms associated with smooth muscle spasms, such as abdominal pain, cramping, and discomfort. It may also help alleviate other symptoms commonly associated with IBS, such as bloating, gas, and altered bowel habits.
Dosage and Administration: Dicyclomine hydrochloride is typically taken orally in tablet form, usually before meals or as directed by a healthcare provider. The dosage may vary depending on the individual's age, medical condition, and response to treatment. It's important to follow the prescribed dosage and administration instructions carefully.
Side Effects: Common side effects of dicyclomine hydrochloride may include dry mouth, blurred vision, dizziness, drowsiness, constipation, difficulty urinating, and headache. These side effects are usually mild and transient, but individuals should report any persistent or severe symptoms to their healthcare provider.
Contraindications: Dicyclomine hydrochloride is contraindicated in individuals with a known hypersensitivity or allergy to the medication or its components, as well as in individuals with certain medical conditions such as glaucoma, myasthenia gravis, severe ulcerative colitis, paralytic ileus, or toxic megacolon.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.2 | 0.9 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.2 | 0.55 |
| Allergies | 6.3 | 4.5 | 0.4 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 6.4 | 6.2 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1 | 3.3 |
| Ankylosing spondylitis | 4.5 | 1.8 | 1.5 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 5.2 | 3.4 | 0.53 |
| Atherosclerosis | 2.1 | 2.2 | -0.05 |
| Atrial fibrillation | 4.1 | 3 | 0.37 |
| Autism | 10.9 | 10.6 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2 | -1.22 |
| Carcinoma | 4.6 | 2.6 | 0.77 |
| Celiac Disease | 2.5 | 3.8 | -0.52 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 5.1 | 6.1 | -0.2 |
| Chronic Kidney Disease | 4.2 | 3.4 | 0.24 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 2 | 0 |
| Chronic Urticaria (Hives) | 1.4 | 1.7 | -0.21 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.3 | 0.08 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.6 | 2.2 | 2.91 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.4 | 3 | -0.25 |
| COVID-19 | 8.8 | 12 | -0.36 |
| Crohn's Disease | 9.2 | 6.9 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 3.3 | 1.4 | 1.36 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 11.4 | 8.8 | 0.3 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.4 | -0.04 |
| Endometriosis | 3 | 2.1 | 0.43 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.7 | 2.2 | 0.68 |
| erectile dysfunction | 2 | 0.3 | 5.67 |
| Fibromyalgia | 2.5 | 2.4 | 0.04 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 4.3 | 0.12 |
| gallstone disease (gsd) | 3.8 | 1.6 | 1.37 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 1.2 | 0.75 |
| Generalized anxiety disorder | 3.3 | 2.5 | 0.32 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 1.3 | 0.31 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 4.4 | 2.2 | 1 |
| Heart Failure | 4.1 | 2.3 | 0.78 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.2 | 0.6 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 2 | 2.2 | -0.1 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.1 | 5.7 | -0.12 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.3 | 0.8 | 3.12 |
| IgA nephropathy (IgAN) | 1.9 | 4.4 | -1.32 |
| Inflammatory Bowel Disease | 8 | 9.5 | -0.19 |
| Insomnia | 2.3 | 3.5 | -0.52 |
| Intelligence | 1.3 | 0.5 | 1.6 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8 | 5.6 | 0.43 |
| ischemic stroke | 2.7 | 1.7 | 0.59 |
| Liver Cirrhosis | 7.5 | 5.4 | 0.39 |
| Long COVID | 7.5 | 8.5 | -0.13 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1 | 1.6 | -0.6 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.9 | 0.33 |
| ME/CFS with IBS | 1 | 2.4 | -1.4 |
| ME/CFS without IBS | 1.9 | 2.2 | -0.16 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1 | 1 | 0 |
| Metabolic Syndrome | 7.6 | 8.3 | -0.09 |
| Mood Disorders | 11.4 | 7.8 | 0.46 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.1 | 14 |
| Multiple Sclerosis | 7.5 | 6.5 | 0.15 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.7 | -8 |
| Neuropathy (all types) | 1.2 | 2.1 | -0.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 5.5 | -0.17 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.4 | 9.9 | 0.05 |
| obsessive-compulsive disorder | 5.3 | 4.8 | 0.1 |
| Osteoarthritis | 2.6 | 1.6 | 0.63 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 9.1 | 7.1 | 0.28 |
| Polycystic ovary syndrome | 7.1 | 3.7 | 0.92 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.5 | -0.25 |
| Primary sclerosing cholangitis | 2.4 | 3 | -0.25 |
| Psoriasis | 3.5 | 3.7 | -0.06 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.4 | 4.7 | 0.79 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 6.7 | 3.5 | 0.91 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.8 | 3.1 | -0.11 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.1 | 16 |
| Stress / posttraumatic stress disorder | 3.1 | 3.2 | -0.03 |
| Systemic Lupus Erythematosus | 4.9 | 2.5 | 0.96 |
| Tic Disorder | 1.5 | 1.7 | -0.13 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 4.5 | 3.9 | 0.15 |
| Type 2 Diabetes | 8.9 | 8.6 | 0.03 |
| Ulcerative colitis | 5.4 | 6.9 | -0.28 |
| Unhealthy Ageing | 5.9 | 2.9 | 1.03 |
| Vitiligo | 2.5 | 2 | 0.25 |
